The report for CRH Medical is updated and rated Speculative Buy at U.S. $3.45 or Canadian $4.49. While nominally a Canadian company it is in fact a 100% U.S. company in substance and my report is in U.S. dollars.
This company was added to the site rated Buy on October 9, 2016 at $4.32 as a growth-by-acquisition company that appeared to offer reasonable value. The stock then approximately doubled. But then very bad news came as it was announced that the company would have to reduce its government-controlled prices for its services. In the confusion about its future profitability that followed, the stock briefly fell under $2 in the late Fall of 2017 before beginning a good recovery. We rated it (lower) Strong Buy on November 3, 2017 at U.S. $1.85. It now appears that, as we suspected, the company is still nicely profitable in 2018 even with the reductions in its fees. The growth model remains intact. It’s still a small company and its accounting is complex. It appears to offer reasonable value.